Scott A. Reines, MD, PhD
Scott Reines has broad drug development experience obtained as a senior executive in pharmaceutical R&D, and currently consults for biotech and pharmaceutical companies as well as for venture capital firms. In addition, he is a member of the Board of Directors of KidsPeace Inc., a non-profit national psychiatric service provider that addresses the behavioral and mental health needs of children.
During his career Dr. Reines has been responsible for the development of many important drugs in five different therapeutic areas. As Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson, he oversaw the development and approval of INVEGA and INVEGA SUSTENNA for schizophrenia, NUCYNTA for severe pain, REMINYL extended release for Alzheimer’s disease, RISPERDAL CONSTA for schizophrenia and bipolar disorder, RISPERDAL for treatment of the behavioral manifestations of autism, and TOPAMAX for prevention of migraine headache and treatment of epilepsy.
Before moving to J&J, Dr. Reines served at Merck as Vice President, Clinical Research with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. At Merck he was responsible for the development of EMEND for prevention of chemotherapy-induced nausea and vomiting, MAXALT for treatment of migraine headache, SINEMET-CR for Parkinson’s disease, and TRUSOPT, COSOPT, and TIMOPTIC-XE for prevention of glaucoma. While at Merck he also oversaw the conduct of the first large, multicenter trial of a COX-2 inhibitor for prevention of Alzheimer’s disease.
Dr. Reines received his BS magna cum laude in chemistry from Cornell University, his PhD in bio/organic chemistry from Columbia University, and his MD from Albert Einstein College of Medicine. Following this he completed a psychiatric residency at Montefiore Hospital in New York City and obtained Board certification in psychiatry. He has published in numerous scientific journals including Science, JAMA, NEJM, and the ACNP journal Neuropsychopharmacology. He recently served as the first industry co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and previously served for five years on the National Drug Abuse Advisory Council and its Bioethics Task Force.
During his career Dr. Reines has been responsible for the development of many important drugs in five different therapeutic areas. As Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson, he oversaw the development and approval of INVEGA and INVEGA SUSTENNA for schizophrenia, NUCYNTA for severe pain, REMINYL extended release for Alzheimer’s disease, RISPERDAL CONSTA for schizophrenia and bipolar disorder, RISPERDAL for treatment of the behavioral manifestations of autism, and TOPAMAX for prevention of migraine headache and treatment of epilepsy.
Before moving to J&J, Dr. Reines served at Merck as Vice President, Clinical Research with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. At Merck he was responsible for the development of EMEND for prevention of chemotherapy-induced nausea and vomiting, MAXALT for treatment of migraine headache, SINEMET-CR for Parkinson’s disease, and TRUSOPT, COSOPT, and TIMOPTIC-XE for prevention of glaucoma. While at Merck he also oversaw the conduct of the first large, multicenter trial of a COX-2 inhibitor for prevention of Alzheimer’s disease.
Dr. Reines received his BS magna cum laude in chemistry from Cornell University, his PhD in bio/organic chemistry from Columbia University, and his MD from Albert Einstein College of Medicine. Following this he completed a psychiatric residency at Montefiore Hospital in New York City and obtained Board certification in psychiatry. He has published in numerous scientific journals including Science, JAMA, NEJM, and the ACNP journal Neuropsychopharmacology. He recently served as the first industry co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and previously served for five years on the National Drug Abuse Advisory Council and its Bioethics Task Force.